Partner David Simon was featured in a Compliance & Ethics article, “Compliance Challenges in India: Why Your Program May Not Translate,” in advance of the Annual Compliance & Ethics Institute where Simon will participate in a panel on the same topic. The article featured a whistleblower scenario and walked through suggested steps in-house counsel, outside U.S. counsel and Indian counsel may take to evaluate the issue. Simon provided insights from an outside counsel perspective and said, “I understand the real and legitimate morale and disruption concerns this scenario raises … I would recommend taking a few reasonable, but tailored investigative steps to test the ‘corrupt sales agent’ allegation.”
Author(s)
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.